Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 4/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515600 | 0.97 | CETP (0.46) | CETPPPARDPPARAMAPTPARP1 | |
| SCHEMBL4521400 | 0.95 | CETP (0.44) | CETPPPARDPPARAMAPTPARP1 | |
| SCHEMBL4498481 | 0.93 | POLB (0.44) | CETPPPARDPPARAMAPTTP53 | |
| SCHEMBL4511561 | 0.92 | CETP (0.43) | CETPPPARDPPARAMAPTALDH1A1 | |
| SCHEMBL4522410 | 0.91 | PPARD (0.44) | CETPPPARDPPARAMAPT | |
| SCHEMBL4516952 | 0.91 | CETP (0.43) | CETPPPARDPPARAMAPTTP53 | |
| SCHEMBL4517041 | 0.90 | CETP (0.41) | CETPPPARDPPARAMAPTTP53 | |
| SCHEMBL4520889 | 0.89 | MAPT (0.46) | CETPPPARDPPARAMAPTALDH1A1 | |
| SCHEMBL4523286 | 0.88 | CACNA1G (0.42) | CETPMAPTALDH1A1TP53LMNA | |
| SCHEMBL4522087 | 0.87 | PPARD (0.59) | CETPPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203908-A1 | Activator for Peroxisome Proliferator-Activated Receptor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1897872-A1 | ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Nippon Chemiphar Co., Ltd. (JP) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203908-A1 | Activator for Peroxisome Proliferator-Activated Receptor | PPARA, PPARG, PPARD | CETP 1172/4885PPARD 3/4885PPARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.